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ABSTRACT
Antibiotic restrictions present difﬁcult choices for physicians, patients and payors. Physicians must
choose between the welfare of the patient and the directive of healthcare systems to restrict antibiotics.
These may be supported with incentives or penalties, causing a conﬂict of interest. The patient has an
expectation of best care, but will often be unaware of antibiotic restriction policies and is therefore not
fully informed about his/her treatment. For payors, reducing the volume of antibiotic prescribing
and ⁄ or prescribing less expensive antibiotics are apparently attractive targets for cost savings. However,
we are only now beginning to understand the downstream consequences of restricting antibiotics on
outcomes and costs. We are hampered by the lack of a universal ethical framework and information on
outcomes. In addition, the concept of ‘effective’ or ‘best’ therapy will vary among different groups.
Balancing the risks of treating or not treating with antibiotics is complex. Suboptimal therapy, that fails
to eradicate the bacterial infection, exposes the patient to the risk of poor outcome, adverse events and
the wider risk of antimicrobial resistance. Failure to treat where the risk of a poor outcome exceeds the
risk of an adverse event is also ethically unacceptable. The key to rational antibiotic prescribing is to
identify those patients who need antibiotic therapy and optimise therapy to achieve the fastest bacterial
and clinical cure. We are only now beginning to assemble the information and tools to be able to make
such decisions. Above all, we should treat on the basis of knowledge.
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INTRODUCTION
It is undisputable that antibiotics have signiﬁ-
cantly reduced mortality and morbidity due to
infectious diseases. However, since the develop-
ment of antibiotic resistance, diseases that we had
thought were conquered, at least in the developed
world, are reappearing. Two well-publicised
examples are the re-emergence of tuberculosis
and sepsis due to methicillin-resistant Staphylo-
coccus aureus. In respiratory tract infection, the
emergence and spread of resistance, particularly
in Streptococcus pneumoniae, continues to constrict
the range of effective antibiotics available.
Unlike most other therapies, antibiotic prescri-
bing is directed towards the pathogen, rather than
the patient. This may cause a conﬂict between
what is best for the individual patient and what is
best for the ecological situation in terms of
maintaining antimicrobial efﬁcacy in the face of
increasing resistance.
The increase in prevalence and worldwide
dissemination of resistance has led to calls for
the restriction of antibiotic prescribing [1–3].
Although there have been numerous guidelines
advocating the use of antibiotics only for bacterial
infection and highlighting the overuse of antibi-
otics for viral infection, diagnosis of bacterial
infection remains a challenge and it is not clear
which patients are at risk of poor outcome. In
addition, antibiotic resistance is multifactorial,
involving host, pathogen and antibiotic interac-
tions, and is complicated by the spread of resist-
ant clones. Antibiotics also differ in their potential
to induce and select for resistance. It is therefore
not clear where the balance lies between ensuring
effective clinical therapy and managing resist-
ance, and tension can arise in deciding between
managing for future use (reserving new agents)
and prescribing the most effective agents (i.e.,
those that maximise bacterial eradication).
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Restrictions on the use of antibiotics in general,
those of certain antibiotic classes or individual
agents are becoming more widespread. There are
a number of ethical issues raised by restricting
antibiotic prescribing. Above all, there is preced-
ent in other diseases to use the best agent as ﬁrst-
line therapy, for example, in tuberculosis, human
immunodeﬁciency virus infection (HIV) and can-
cer. However, it often the ‘best’ therapy that is
targeted for antibiotic prescribing control. These
agents are usually the newer, more expensive
products, often developed to overcome existing
resistances.
In order to control increases in the prevalence
of antibiotic-resistant bacteria in the community,
there is no doubt that physicians must optimise
their use of antibiotics. This paper examines the
impact of antibiotic restrictions on the ethical
landscape of prescribing antibiotics, particularly
in the case of respiratory tract infections, and
suggests that a more informed and ﬂexible
approach to controlling resistance and optimising
antibiotic prescribing is required.
UNIVERSAL ETHICAL FRAMEWORK?
All of us are familiar with the Hippocratic oath.
We conceptualise the oath as a universal binding
agreement between a doctor and society, as an
ethical benchmark. We see it reaching back
through generations of physicians, deﬁning our
responsibilities and linking us together across the
centuries. In fact, the reality is not quite so
romantic. Firstly, the oath was probably written
by Pythagorean healers in the 4th century BC
rather than Hippocrates. Secondly, it only became
popular in the last century; in 1928 only 24% of
medical schools in the USA and Canada used the
oath compared with 98% in 1993 [4].
The classic oath forbade the use of surgery,
euthanasia and abortion, and required physicians
to be held accountable for their actions. Louis
Lasagna proposed a new oath in 1964, updated to
reﬂect changes in moral and social tenets. Other
alternatives include the Prayer of Maimonides,
written by the 12th-century Jewish physician, and
the Declaration of Geneva, composed by theWorld
Medical Association in 1948 and updated in 1983.
Thus, in reality, there is no single, common,
modern Hippocratic oath. A 1993 survey found
that only one of the 150 medical schools that
responded used the classical version of the oath,
45 used a shorter (165 vs. 335 words) modern
version, 22 used oaths which were based on the
Hippocratic oath but included signiﬁcant modiﬁ-
cations, and one used an unknown version of the
Hippocratic oath. In addition, ten used the ori-
ginal 1948 Declaration of Geneva, 24 used the
1983 revision of that Declaration, 15 used the
Osteopathic oath, ﬁve used the Oath of Louis
Lasagna, four used the Prayer of Maimonides,
and 20 used other unique oaths. In 11 schools,
graduating students could select from one of
several existing oaths or write their own unique
oath. Importantly, most modern versions of the
oath are ‘consequence free’, i.e., there are no
penalties for breaking it. Thus, one wonders
whether the Hippocratic oath (or versions of it)
really represent a universal ethical framework?
In the 1980s, in response to these perceived
discrepancies, physicians and ethicists in the USA
and UK proposed a new ethical basis, which was
focused on informing clinical decision making
rather than deﬁningmoral boundaries. There were
four main components to this ethical framework.
Beneﬁcence
Beneﬁcence means literally ‘do good and avoid
evil’. This, of course, generates an open-ended,
moral question: what is good and what is evil?
We do not have to think very hard before arriving
at numerous examples of a medical intervention
that is considered ‘good’ in one social group and
‘evil’ in another. The major issues of abortion,
euthanasia, fertility treatment and genome re-
search are endlessly debated in terms of ‘good’
and ‘evil’ as a consequence of their religious
signiﬁcance rather than their medical merit.
Nonmaleﬁcence
‘Primum, non noccere’ is often thought to be the
basic principle of the Hippocratic oath, but was
not, in fact, included in the ancient version.
Rigorously interpreted, it implies that one cannot
act if doing good also causes some harm. How-
ever, as most ‘best’ actions have some harmful
consequences, should we do nothing? The prin-
ciple of double effect gives us a more realistic
interpretation; an intended and otherwise unat-
tainable good effect, plus an unintended yet
foreseen evil effect is ethically acceptable,
provided there is a proper balance between the
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intended good and the permitted evil. Simplistic-
ally, this can be seen as a risk–beneﬁt approach.
The assessment of risk and beneﬁt is, of course,
entirely contextual.
Autonomy
Autonomy – the capacity for self-determination –
is exercised through informed consent, the land-
scape of which is constantly changing. A doctor
may feel overwhelmed when a patient comes into
the ofﬁce with pages and pages of material from
the internet, but if the patient requires that level of
information and discussion to consent to therapy,
then is it the doctor’s responsibility to accept and
provide that? If not, who else? Perhaps the
movement for patients to take greater control of
their health and even over clinical decisions is in
response to the need for informed consent, a need
that was not being met through the traditional
consultation. In settings where educational and
literacy levels are low, is it possible for a patient to
provide informed consent at all?
Justice
Justice requires that everyone receive equitable
access to healthcare. Of course, on a global scale,
this is currently unachievable. Within healthcare
systems, resource allocation decisions such as
rationing of services, should not be affected by a
person’s status or the nature of the illness. How
should rationing decisions therefore be made?
ETHICS AND ANTIBIOTIC
RESTRICTION
All four of the principles outlined above are
highly context dependent. Their application will
be consistent only within controlled healthcare
systems or homogeneous social groups. They may
therefore be somewhat of an evasion – universally
applicable, but meaningless against a diverse
moral background. They do, however, provide
us with a checklist against which we can examine
our decisions within a given context, in this case,
antibiotic prescribing.
Physician perspective
Physicians are caught between their responsibil-
ities to the patient, the need to preserve antibiotics
for future use and their position as gatekeepers
for health systems that may impose incentives
and penalties based on prescribing habits. The
relationship among these roles has the potential to
create ethical tension.
Generally, physicians prefer to use therapy that
they perceive to be best for their patients, rather
than consider the wider problem of resistance.
Best therapy will result in clinical cure, without
the need for a return visit for follow-up medica-
tion or to treat the adverse events of therapy.
In a survey of 400 general physicians and 429
infectious disease specialists, antibiotic resistance
was ranked lowest among seven determinants of
antibiotic choice for community-acquired pneu-
monia [5]. Thus, physicians appear to be motiva-
ted by the desire to treat the individual, rather
than to protect society from antibiotic resistance.
However, would the ethical balance be different if
the risk of poor outcome was incorporated?
A further report based on this survey tested this
hypothesis [6]. Responses were available for 398
general physicians and 429 infectious disease
specialists. Clinical vignettes prompted respond-
ents to select the level of resistance to a hypo-
thetical older antibiotic at which they would
prefer a newer antibiotic without any current
resistance in the treatment of a patient with
pneumococcal pneumonia. Site of care was used
as a proxy for disease severity. The resistance
threshold for switching to a newer antibiotic was
reduced signiﬁcantly as disease severity in-
creased. Generalists were more sensitive to dis-
ease severity than specialists.
These reports highlight the dissociation be-
tween the complex decision-making process at
the point of care and guidelines and restrictions
based on populations and imposed by health
systems. This conﬂict can be looked at in terms of
the principle of beneﬁcence – is it good or evil to
treat the individual without regard for the risk to
society from resistance? Perhaps physicians are
applying the principle of nonmaleﬁcence, with
the double effect principle weighted in favour of
the more tangible good they feel that they can do
for the patient in their consultation room vs. the
unintended harm of resistance, which is more
difﬁcult to conceptualise or quantify.
The provision of incentives and penalties for
physicians, based on their prescribing habits,
adds a further dimension to the clinical decision.
Should physicians prescribe what they think to be
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best and risk a penalty ⁄ lose an incentive, or
should they prescribe in line with the policy even
if it conﬂicts with their clinical judgment? What is
‘good’ or ‘evil’ or somewhere in between?
Different physicians within a healthcare system
will resolve these dilemmas differently; one may
follow an antibiotic prescribing policy to the
letter, while another will ignore it completely.
This will create a mosaic of prescribing patterns
inﬂuenced by physicians’ responses to the policy
as much as the variability in patients’ clinical
presentation. This variability undermines the
principle of justice, i.e., equal access for all.
Where the incentives or penalties are great,
there may be a complete shift in prescribing
habits. Unfortunately, very few data are available
concerning the consequences of these shifts on
patient outcomes. There is some evidence that
patients do suffer when medicines are restricted.
A previous article [7], and the article by Price in
this supplement (page 3) show a possible rela-
tionship between decreased antibiotic prescribing
in the UK and increased mortality from respirat-
ory tract infections. However, there is generally
no plan to follow up on patient outcomes after
interventions to reduce antibiotic prescribing.
Patient perspective
It is unlikely that patients will have experienced a
direct effect of antibiotic resistance. They may be
aware of resistance as an issue and it may be
explained to them as a reason for withholding
antibiotic therapy. However, if the physician
determines that antibiotic therapy is required,
the majority of patients will expect the best
therapy. From the patients’ perspective, this is
therapy that results in the most rapid cure and
return to normal activities, and that is well
tolerated and safe.
Most patients will be unaware that antibiotic
therapy may be restricted. Does this undermine
trust in their doctor to do what is best for them?
Are patients providing informed consent when
they are unaware that the best therapy may be
denied? The principle of autonomy, the right to
self-determination, may not be met when physi-
cians are placed in a position of choosing between
restrictive policies and belief in their clinical
skills.
There is an increasing move for patients to take
responsibility for their healthcare. Information is
more abundant than ever and it may no longer be
acceptable or possible to keep patients in the dark
regarding new therapies. In the case of HIV
infection, patients have been successful in lobby-
ing for new drugs to be made available, and
similar campaigns have been conducted for other
chronic diseases. In antibiotic prescribing for an
acute infection, certainly in the USA where direct-
to-consumer advertising is permitted, patients
may have already formed an opinion as to their
required treatment when they enter the physi-
cian’s ofﬁce. Is it ethical for the physician to
dissuade them of that opinion, even if it is
reasonable, in order to meet prescribing targets?
Payor perspective
Cost is an important consideration for payors.
However, this is not just the cost of initial
antibiotic therapy and the initial consultation,
but includes the cost of poor outcomes and the
possible downstream cost of resistance. Import-
antly, there may be different payors in different
parts of the healthcare system meeting different
costs, with little consideration for what lies ‘over
the wall’. For example, a general practice may
have an incentive to reduce antibiotic prescribing,
but if this results in worse outcomes, the cost of
any increase in hospitalisations may be borne by a
different payor in tertiary care.
In socialised healthcare systems and managed
healthcare organisations, payors have a commit-
ment to the individual patient, but primarily to
the collective of people included in the group.
From the payor perspective, antibiotic restrictions
are an attempt to balance the cost of poor outcome
for the individual with the cost of initial treatment
plus the cost of resistance. However, is this ‘just’
for society? Are the costs of poor outcomes
greater or less than the cost of resistance?
Although there are some hospital-based studies
on the costs of resistance, very little information
with which to address this question in the
community setting is available.
ANTIBIOTIC USE, OUTCOMES,
RESISTANCE AND COST
Resistance and outcomes
Unfortunately, in many regions, antibiotic resist-
ance has reached prevalences that impact on
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patient outcomes. The global spread of resistant
S. pneumoniae illustrates this point (Table 1) [8].
Although the prevalence of penicillin resistance in
S. pneumoniae is high in Southern Europe, the
USA and the Far East, the impact on outcomes in
the community setting is not clear. In the hospital
setting, penicillin resistance can be overcome by
using high-dose intravenous therapy, providing
sufﬁcient concentrations to eradicate resistant
strains [9].
The situation for macrolide resistance in
S. pneumoniae is more alarming. In a matched,
case-control study, breakthrough bacteraemia
during macrolide or azalide therapy for commu-
nity-acquired pneumonia was signiﬁcantly more
likely among patients infected with an erythro-
mycin-resistant pneumococcus [10]. Interestingly,
both the low-level efﬂux resistance and high-level
methylase resistance mechanisms were clinically
relevant to therapy failure [10]. In addition, novel
macrolide resistance mechanisms have been
reported in several cases of macrolide treatment
failure in community-acquired pneumonia due to
the on-therapy development of resistance [11,12].
In the case of ﬂuoroquinolones, failures in
community-acquired pneumonia and acute exac-
erbations of chronic bronchitis have been reported
with the pharmacodynamically inadequate ﬂuoro-
quinolone, levoﬂoxacin. Pharmacokinetic ⁄phar-
macodynamic investigations indicate that
ﬂuoroquinolone activity in vivo is concentration
dependent. Thus, a higher ratio of Cmax: MIC or
AUC:MIC is predictive of better antibacterial
activity. For levoﬂoxacin, the AUC:MIC ratio
against S. pneumoniae is 48, compared with 68
for gatiﬂoxacin and 192 for moxiﬂoxacin [13].
Levoﬂoxacin failures due to levoﬂoxacin-resistant
pneumococci have been documented in 89
patients in case studies, clinical trials and epide-
miological investigations [13,14], and on-therapy
selection of ﬂuoroquinolone resistance with levo-
ﬂoxacin has also been described in a careful well-
designed study [15]. In contrast, very few or no
failures have been reported for moxiﬂoxacin or
gatiﬂoxacin, probably because of their higher
in-vitro activity and more favourable pharmaco-
dynamics ⁄pharmacokinetics compared with levo-
ﬂoxacin.
Thus, we have already reached a situation
where outcomes are being compromised by the
use of ineffective antibiotic therapy. In many
regions, the time to reserve more potent antibiotic
therapy has passed; we need to ensure rapid
bacterial eradication and for this we need to use
the most effective therapy at the optimal dose and
duration.
Suboptimal antibiotic prescribing and
resistance selection
The continued use of suboptimal agents also has
an ecological consequence. In a mixed bacterial
population with both antibiotic susceptible and
resistant strains, antibiotic therapy that fails to
eradicate resistant bacteria enriches the popula-
tion for these strains, accelerating the selection of
resistance (Fig. 1). In contrast, antibiotic therapy
that maximises bacterial eradication minimises
the potential for resistance selection. In addition,
Table 1. The prevalence of antibiotic resistance (%) in
Streptococcus pneumoniae: LIBRA TARGETed surveillance
study, 2003 [8]
Country
(No. centres,
No. isolates) AZI PEN A ⁄C CTX LEV GAT MXF
France (6, 449) 52.1 35.9 2.0 2.5 1.8 1.6 0.2
Germany (5, 260) 20.8 0.8 0 0 0 0 0
Italy (12, 540) 39.1 8.5 0.7 0.9 3.0 2.6 0.4
Spain (3, 232) 28.0 24.6 7.3 0 0 0 0
Mexico (3, 203) 21.2 19.7 0 0.5 1.5 0.5 0
South Africa
(2, 167)
48.5 47.9 13.8 4.2 0.6 0.6 0.6
USA (20, 1382) 29.7 23.7 8.0 2.5 0.9 0.8 0.4
AZI, azithromycin; PEN, penicillin; A ⁄C, amoxicillin ⁄ cla-
vulanic acid; CTX, ceftriaxone; LEV, levoﬂoxacin; GAT,
gatiﬂoxacin; MXF, moxiﬂoxacin.
Selection
pressure due
to sub-optimal
antimicrobial
therapy
Multiplication
Selection
Resistant strain
Susceptible strain
Fig. 1. Antimicrobial therapy that fails to eradicate resist-
ant strains can enrich the bacterial population for these
strains.
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rapid bacterial eradication minimises the number
of bacterial generations exposed to antibiotic and
reduces the potential for de novo resistance
emergence.
An example of the consequences of inappro-
priate use on resistance is given by the replace-
ment of ciproﬂoxacin with oﬂoxacin or
levoﬂoxacin in hospital formularies concerning
Pseudomonas aeruginosa resistance. All of these
agents are ﬂuoroquinolones and all have activity
against P. aeruginosa, though ciproﬂoxacin is the
most active agent. Peterson et al. found that, in a
tertiary medical centre, after switching to oﬂoxa-
cin, P. aeruginosa susceptibility to ciproﬂoxacin
decreased by 21% and to oﬂoxacin by 23% over a
2-year period. Switching back to ciproﬂoxacin
resulted in a recovery of 7% in susceptibility to
ciproﬂoxacin within 6 months [16]. A study
across 109 hospitals found that greater oﬂoxacin
use was associated with lower P. aeruginosa sus-
ceptibility [17]. Similarly, a study of 174 hospitals
revealed a signiﬁcant correlation between oﬂoxa-
cin and levoﬂoxacin use, and decreased P. aeru-
ginosa susceptibility [18]. Signiﬁcant relationships
have been demonstrated in other studies between
the use of levoﬂoxacin and decreased susceptibil-
ity of P. aeruginosa, Escherichia coli and Klebsiella
pneumoniae to ﬂuoroquinolones [19–22].
In community-acquired respiratory tract infec-
tions, there is some evidence that the use of more
active agents that maximise bacterial eradication
is less likely to lead to resistance than suboptimal
therapy. Observations have been made regarding
increased ﬂuoroquinolone use and increases in
ﬂuoroquinolone resistance in S. pneumoniae, in
particular in Canada, the USA and Hong Kong
[23–25]. In most cases, this relationship has been
inferred, rather than statistically analysed, but it
appears to be associated with increased levo-
ﬂoxacin use. A recent and extensive analysis of
data from the USA investigated this association
more rigourously [25]. A signiﬁcant relationship
between levoﬂoxacin use by geographic region
and resistance was found when the study year
was removed from the model (p < 0.001) [25]. The
removal of the study year was necessary to show
signiﬁcance in this relationship because of a
competing colinearity caused by the increase in
levoﬂoxacin use each year. Relationships between
the use of other ﬂuoroquinolones, such as moxi-
ﬂoxacin and gatiﬂoxacin, and MICs were not
signiﬁcant [25]. The authors suggested that the
ability of levoﬂoxacin use to drive resistance was
due to its inadequate pharmacokinetic ⁄pharmaco-
dynamic proﬁle [25].
Impact of antibiotic restrictions on costs
Restrictive formulary policies that either limit
drugs within a medication class or exclude certain
classes of agents altogether may not, in fact,
reduce costs. In a 1996 study of the cost of care for
12 997 patients in six health maintenance organ-
isations (HMOs), increased overall patient care
costs were positively correlated with restrictive
formulary practices [26]. Those HMOs with the
most restrictive formularies and the greatest use
of generic agents had the highest cost of care,
whereas those with open formularies had lower
costs [26]. This study suggests that viewing
formulary decisions too narrowly within an eco-
nomic framework can result in unintended out-
comes, including increased costs [26].
There are few data available regarding the
impact of formulary restriction on outcomes in
the community setting. However, one study of
primary practices in Australia shows that we
cannot be complacent in our assumptions regard-
ing the impact of antibiotic restriction [27]. This
study aimed to determine the impact of an
Australian Government directive targeted at
reducing the use of amoxicillin ⁄ clavulanate.
Importantly, no advice was given concerning an
alternative. Based on data from 34 242 patients
and 318 234 recorded patient visits, the investi-
gators found that there was a shift away from
best-practice prescribing, and a signiﬁcant associ-
ation between the rate and cost of process-of-care
and adverse patient outcomes, and the decrease
in amoxicillin ⁄ clavulanate prescription share [27].
In essence, this policy of restriction caused a
decrease in the quality of antibiotic prescribing
and thus increased costs. The increase in process-
of-care costs was possibly due to doctors feeling
that they had to perform more investigations to
justify the use of the restricted agent [27].
This issue is not just conﬁned to antibiotic
prescribing. A study of primary practices that had
formularies restricted to a single or exclusive
selective serotonin reuptake inhibitor revealed
that patients who needed to switch antidepres-
sants remained in treatment 50% longer and cost
approximately 50% more to treat in a more costly
treatment setting [28]. It would appear that, in this
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case, giving the primary care physician several
antidepressant choices provided more options to
continue treatment in the less expensive primary
care setting [28].
Restrictive formularies allow the use of the
permitted (often less expensive) medicines relat-
ively freely, while deﬁning even moderate use of
the restricted (often more expensive) agents as
‘overuse’ [29]. Such policies are divorced from
relative clinical effectiveness or, in the case of
antibiotics, bacteriological eradication and the
potential to induce or select for resistance. These
studies show that disregarding these issues, as
well as broader patient needs, will compromise
the potential to save money from restrictive
formularies.
ETHICAL ¼ RATIONAL ANTIBIOTIC
PRESCRIBING DECISIONS
In the clinic, how can the physician balance
clinical effectiveness, resistance risk, cost and
unnecessary exposure of the patient to adverse
events? Fig. 2 shows the decision matrix for these
four factors against the choice among no therapy,
optimal therapy and suboptimal therapy.
The decision should be based on minimising
overall risk. For example, even if suboptimal
therapy is less expensive per course than optimal
therapy, it carries an increased risk of poor patient
outcome and resistance as well as having some
cost. This represents the worse case option in
terms of risk from all perspectives. Similarly, no
therapy is justiﬁed when the patient would not
beneﬁt from treatment sufﬁciently to outweigh
the risk of adverse events or cost.
Decisions can only be made at the point of
care, based on the physician’s clinical skill.
Currently, we do not have the data to make
accurate risk assessments regarding the
risk:beneﬁt ratio of antibiotic therapy at a
population level. It is unlikely that the data
that are available can be generalised to all
patient populations. Critically, information is
needed on the risk and cost of poor outcomes,
but this is rarely measured in a real practice
setting. Tools to determine ‘risk factors’ for poor
outcome may be helpful, but have to be widely
applicable, based on a large and relevant data
set, and must be validated for the speciﬁc
antibiotic prescribed. For example, the Pneu-
monia Severity Index [30] is sometimes used as
a basis for determining the site of care and need
for broad-spectrum antibiotic therapy [31].
However, this tool has only been validated as
a means of identifying patients at low risk of
mortality [30]. The Pneumonia Severity Index is
heavily weighted by age and co-morbidities, and
thus will fail to identify younger, otherwise
healthy patients with community-acquired
pneumonia who have severe disease and
require antimicrobial therapy [31]. It also ex-
cludes issues such as homelessness, substance
abuse and other medical needs that need to be
considered when deciding site of care or treat-
ment options [32].
In summary, the physician consultation is still
the only point at which a meaningful risk assess-
ment can be made and attempts to control this
decision outside of the consultation are at best
inﬂexible and often, in fact, ﬂawed.
Ethical decision making
In 2001, Burck suggested an overarching ethical
framework for clinical decision making: ‘Above
all, treat on the basis of knowledge’ [33]. This
rhetoric states the ﬁrst ethical responsibility of
scientiﬁc medicine and converts the most widely
used maxim in medical ethics, ‘above all do not
harm’, from a negative to a positive ambition [33].
Based on our knowledge, suboptimal therapy that
fails to eradicate the bacterial infection and
exposes the patient to the risk of poor outcome,
adverse events and antimicrobial resistance can-
not be considered ethical. Failure to treat where
Worse case
BALANCE
Risk of:
Poor
outcome
Adverse
event
Resistance
Drug cost
No treatment
RISK
NO RISK
NO RISK
NO COST
Optimal treatment
NO RISK
RISK
RISK
<<<sub-optimal
>no treatment
COST
Sub-optimal treatment
RISK
RISK
RISK
COST
Fig. 2. Decision matrix for antibiotic prescribing based on
minimising risk.
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the risk of a poor outcome exceeds the risk of an
adverse event due to antibiotic therapy is also
ethically unacceptable. The key to rational antibi-
otic prescribing is to identify those patients who
need antibiotic therapy and then to optimise
therapy to achieve the fastest bacterial and clinical
cure. We are only now beginning to assemble the
information and tools to be able to make such
decisions.
CONCLUSIONS
The decision to restrict an antibiotic may be taken
out of the physician’s hands or physicians may be
penalised if they fail to comply with policy.
Worryingly, the impact of these restrictions on
patient outcomes is seldom investigated and
remains, for the most part, unknown. Certainly
in Europe and the USA, regulatory authorities are
making approval, pricing and reimbursement
decisions that impact on the choices of antibiotics
available to clinicians. This may conﬂict with their
role to approve safe and effective medicines, and
undermine further research and development.
These regulatory authorities may also be involved
in policy decisions at government level and
educational campaigns to reduce antibiotic pre-
scribing. National campaigns are often targeted to
reduce the frequency of prescribing, rather than
attempting to improve the quality of prescribing.
There is a suspicion that, in some cases,
reducing antibiotic prescribing is seen as an easy
way for healthcare systems to reduce costs, rather
than to improve healthcare for patients or manage
resistance. Prescribing for respiratory tract infec-
tions is a common target for control, possibly
because, in many cases, disease will be acute and
self-limiting. However, adverse outcomes are not
uncommon, particularly for community-acquired
pneumonia. Potential complications include ful-
minant clinical courses and patients may deteri-
orate rapidly without intervention. In acute
exacerbations of chronic bronchitis, more effective
antimicrobial therapy may reduce the time to the
next exacerbation [34,35]. It should also be
remembered that most of the studies for antibiotic
restrictions have been performed in a hospital
setting, where their impact can be more easily
measured and outcomes determined. This is far
more difﬁcult in the community setting and
antibiotic restrictions may result in unintended
consequences.
The situation will be improved with the wide-
spread availability of deﬁnitive diagnostic tests.
However, these will incur a cost and with few
data available on the cost of poor outcomes and
resistance, it may be difﬁcult to justify their
routine use. It will certainly be a test of how
seriously health systems consider the threat of
resistance or whether, in fact, efforts to reduce
antibiotic prescribing are mainly directed at redu-
cing drug expenditures. Despite these reserva-
tions, point-of-care testing for bacterial infection
would greatly inform clinical decision making. In
the meantime, balancing the risks of treating or
not treating with antibiotics remains complex
and, above all, we should treat on the basis of
knowledge.
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